October 21, 2024

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize

(EDITORIAL from Korea Times on Oct. 21)

The National Intelligence Service (NIS) confirmed on Friday that North Korea has deployed troops to assist Russia in its war against Ukraine. At a National Security Council (NSC) meeting, the spy agency revealed aerial images showing hundreds of Nort…

Leaders of rival parties agree to hold 2nd official talks

The leaders of the ruling People Power Party (PPP) and the main opposition Democratic Party (DP) agreed Monday to hold another round of official talks following their first meeting last month, a PPP official said.

PPP leader Han Dong-hoon “gladly ac…